Member Info for Doc.Daneeka

I'm talking about AMR dummy. It's why it's in this thread.

RM will stick to the facts - ie how SNG works and where it is in the trialing process. This might be an adjusted version of PM's ACT speech or something new. He has nothing to say on SNG's efficacy against COPD or Asthma that can be stood up.
If the new science writer has actually started work he might craft something along the lines of Prion25's thinking from yesterday morning, and maybe add in some of the promising Ifn work that supports the SNG case as a possible broader treatment

" What will RM have to offer ? There is evidence that alternative pulmonary therapy using interferon beta activates neutrophils which combat infection The use of steroids (dexamethasone) causes black fungus diseases because of immunosuppression wheres interferon beta does not and moreover protease inhibitors etc induce viral resistance whereas interferon beta does not imo GLA "

If you want to be bullish you might also suggest that Richard Marsden has taken this little gig as he is in the US in early September anyway, to fry a much bigger fish ....

Manifesto misses the point again !! Wpa5 wasn't arguing one way or the other - just in very broad stroke terms suggesting the two mindsets that exist and compete on this board and possibly inside each of us. But hey it gave you the chance to sing the company song again
Yesterday - by the way - was pathetic. Your attack on Ghia - after his jocular riposte to Monte's very funny conference post - was beneath contempt. Just as your earlier comment about the millions the board willl be missing out on struck a horrible note and effectively ended the decent debate we might have had.
You are always wrong - every single day. Over-ramping minor news and attacking anything that offers an alternative perspective. I won't add any more - but be aware that we all see what you are about, and it is truly pathetic.

RM speaking at 3.10 on 7th Sept "Session title to be announced " Listed under the topic heading " Therapeutics ". On his own at the moment but presume this won't be the case by the time it starts.
The conference has an incredible 164 speakers in a facillity with 50k sqm and dozens of potential room configurations. Many events occuring simultaneously (5 in his 3.10 slot)

https://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/agenda.stm

Well done Nessa ! (and Detective Aim )

Not hung up on it Gunto - but I raised it originally so I thought I might respond with what i knew about it.
I also think Stacey misunderstood Org's question. When she said "I try to keep my presentations Higher level" she was talking about the drugs she highlights - rather than addressing the specificity of whether or not every drug trialed was on the slides. Which they were - apart from SNG. She had Brii highlighted twice on that slide and was v keen to talk about it.

**** up rather than conspiracy is what i said at the time and I stand by that - but it IS an omission

Plenty of the drugs on all the slides do not have published results. It's not the answer.

I raised this a couple of times Matterhorn - as a curiosity as much as anything else. Got into trouble as it was considered de-rampy.
Org asked Stacey about it
Org ‘ should I read into it that Synairgen not included etc’
Hi Rob,
I try to keep my presentations higher level, so I would not read into any particular agent not being mentioned in any of them.
Best,
Stacey

Only in as much that if they are actively looking for potential co-trialists in the out-patient setting for the 2 monoclonals that are still in use - they might look favourably on a drug that succeeded on their own Activ2 programme. It's a long shot as we know cost/efficacy ratio is not in Synairgen's favour in the outpatient setting - compared to both of these therapies but they are both being used for the same targeted population that SNG treated so well in Sprinter so there's a chance.

that is interesting - noticed it at the time. Outpatients I believe she was talking about. Paxo and Molnupiravir.

Thanks Hatter here's a study showing how 10 monoclonals fared against BA2.75. The really interesting thing is that whilst it may knock out most of them including half of the Evusheld ****tail - it's the first Omicron variant that Sotrovimab is efficacious against and that is held in large supplies in the US and UK. Sotrovimab is still EUA'd I believe but not used for Omicron patients. I guess they'll throw it back into the fight if BA2.75 takes over. Not sure of any other drugs that have been resurrected after failing.

" Adintrevimab, bamlanivimab, casirivimab, etesevimab, and
imdevimab did not work against BA.2, BA.4/5 and BA.2.75
Importantly, while regdanvimab, sotrovimab, and tixagevimab did not exhibit antiviral
effects against BA.2 and BA.4/5, these three antibodies were functional against BA.2.75,
suggesting that these antibodies can be used for the therapy and prevention of BA.2.75 infection. "

https://www.biorxiv.org/content/10.1101/2022.07.14.500041v1.full.pdf

You're rock solid in my book Palladin. Balanced, measured, overwhelmingly positive and open to all views. In short the perfect contributor to this board.

Aether Strive is safe for now I'm sure. It's funded and planned to accept a wide range of respiratory disease candidates when Covid is over - so it is not entirely dependent on the ebb and flow of political feelings around the pandemic. It's ALL about whether SNG is on it - and we are still a very strong candidate.

That would be a great outcome Jint - some here seem to believe it's possible we'll get onto a flu trial.
Wouldn't be a complete disaster if the covid trialing leads us ultimately in a different direction - but i can't see anyone funding us when we have no flu trial data at all. How would we even be a candidate ? And if Peter Horby is still involved we wouldn't exactly have a friendly face on reception
Therefore the main event is hopefully still Strive as l don't know of any other funded platform trials that are available.

Hold - sound advice - I'll accept it

I dion't ned to defend the quality of my posting to man who spends his whole life trawling the internet for ifn studies and then trying to link them to SNG. My record stands Tommy. I'll call out your junk and Mani's nonsense whenever it crosses the line.
And btw - the science writer hire is only a big deal if Synairgen has a Long Covid ace up its sleeve - which it almost certainly does not.

Ok cool - just as long as you two knew. We have been discussing it a lot so my post is aimed at anyone who was unaware.
Still love your work Tommy - you're my hero. And Mani -pure gold

This is so old - but i completely missed it and haven't seen it discussed. We don't have a single thread (that i can see) about it - but one or two have obliquely referred to it. After Hold4's post I checked and discovered Recovery really is ending in October.
Sure I'm the last to know....
The Recovery team have applied for a year's extension to use remaining funds to finish existing trials - but funding stops in October and no new trialists will be admitted. With so far to go in the remaining trials - remember paxlovid had 200 patients enrolled in the 4 months to the end of July and need 8000. I'd say there's a good chance they will all be pulled. They have to apply for a no-cost extension

Sure I'm the last to know.... and not surprised that the people who did know about it (I'm sure it's been discussed extensively on Reddit ) decided not to bring it here - for the obvious reasons.

Amongst other things it means that Ghia was right to use the word SWITCHING yesterday as that's exactly what the Recovery team are going to do. APOLOGY please Manifesto (just kidding - you don't have the class to apologise)

More importantly it means Recovery is a non starter for SNG - which is not a big deal as they'd never have let us on anyway - and we'd never have completed it - but is a very big deal if this huge change in emphasis is also repeated in the States (which is what JoeyD was talking about yesterday )

STRIVE is safe I'm sure - regardless of the mid terms - at least until we have a new President. And even then a new (god forbid) right wing administration would not be able to immediately end funding.

But it IS an important sea change here. If NHRS believes its work is done - believes that Covid is effectively over - or under control. It's a dark day for funded Covid research and further adds to the terrible tragedy of Feb 21st.

https://tinyurl.com/59nju4kd BMJ link

JoeyD "With the US political landscape and regulatory bodies like CDC changing their views on Covid significantly in the last few days I fear the trial could be shelved. "
Obviously most responses disgreed with this assessement - but Prion said he feared JD was right.
Question is - has the CDC " changed its view on Covid significantly in the last few days "
It all looks like business as usual to me - the same prophylactic and therapeutic drugs available for free to the at-risk or unvaccinated population. Politically the mid terms are coming up - and Fauci has announced he's leaving his post, both of which could impact funding / future planning, but the CDC is still cautioning that Covid is still a real threat and Biden is still in full support of the financial and medical counter measures.

What is this fear based on ?

Morning Ghia Plenty of times when we need to counter speculation or unconfirmed nonsense on here, but if Brand says he's seen it that's probably good enough for the board. And who cares ? It was announced a while ago - it's a standard position that we were all surprised they didn't already have in house. It's only evidence of anything good or bad if it fits people's agendas. They're spending money on a staffer and presumably need this person in the near future - even if it's just to write up the A2 data.

unless they've decided having a staff man is cheaper than the contract fees they were paying - or they know SNG has already been accepted onto STRIVE and are unconcerned about costs - this seems a very odd and expensive hire.
Activ 2 data will be oven ready when it arrives - Sprinter has already been written up - Peer review is taking place elsewhere of course - which really just leaves LC - if there's anything to add on that which we don't know there is yet - or possibly the autoantibody work JD was describing.
We could imagine he/she will be busy working on 2 write-ups. A2 and LC - and will then be sitting in the office playing wordle until whichever trial we are accepted onto delivers in at least a year's time, and probably 18 months to 2 years.